Asset profile
MGD020
Multispecific antibody
Evidence outlook · lead readout
NCT05261191 · Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05261191: This trial had no randomization, no blinding, and no placebo comparison; each small group received a set dose to see how it was tolerated. The posted results are limited to side-effect counts, with no severe or treatment-related severe events reported in any group, but there is no measure here of whether the treatment controlled HIV.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.